(Q33381844)

English

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Fernando Cabanillas

object named as

Fernando Cabanillas

3

0 references

Hagop Kantarjian

9

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

object named as

Luis Fayad

0 references

7

object named as

Larry W Kwak

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Michael Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fredrick Hagemeister

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Peter McLaughlin

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maria A Rodriguez

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yuhong Zhou

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jorge Romaguera

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

113

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2734-2741

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of survival in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Real-time 5'-->3' exonuclease-based PCR assay for detection of the t(11;14)(q13;q32)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23880

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23880

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33381844&oldid=1971904209"